Reducing the burden of lower respiratory tract infections in infants in the Canadian Arctic
- PMID: 28385860
- PMCID: PMC5367989
- DOI: 10.1503/cmaj.161293
Reducing the burden of lower respiratory tract infections in infants in the Canadian Arctic
Comment on
-
Hospital admissions for lower respiratory tract infections among infants in the Canadian Arctic: a cohort study.CMAJ Open. 2016 Oct 17;4(4):E615-E622. doi: 10.9778/cmajo.20150051. eCollection 2016 Oct-Dec. CMAJ Open. 2016. PMID: 28018874 Free PMC article.
-
Cost-effectiveness of palivizumab compared to no prophylaxis in term infants residing in the Canadian Arctic.CMAJ Open. 2016 Oct 18;4(4):E623-E633. doi: 10.9778/cmajo.20150052. eCollection 2016 Oct-Dec. CMAJ Open. 2016. PMID: 28443266 Free PMC article.
References
-
- Canadian immunization guide chapter on influenza and statement on seasonal influenza vaccine for 2016–2017. Ottawa: Public Health Agency of Canada; 2016.
-
- Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact RSV Study Group. Pediatrics 1998;102:531–7. - PubMed
-
- Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003;143:532–40. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources